Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy最新文献

{"title":"Evaluating the Overall Safety of Glucokinase Activators in Patients with Type 2 Diabetes Mellitus.","authors":"Ting-Ting Liang, Min-Jia Cao, Qian Wang, Jia-Shuang Zou, Xiao-Ming Yang, Li-Fang Gu, Fang-Hong Shi","doi":"10.2147/DMSO.S474280","DOIUrl":"10.2147/DMSO.S474280","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the overall clinical adverse events (AEs) associated with glucokinase activators (GKAs) in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>We searched MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov databases from their dates of inception to June 6, 2023, for randomized controlled trials (RCTs) that reported safety data for GKAs in patients with T2DM. A random-effects model was used to obtain a summary odds ratio (OR) with associated 95% Confidence Intervals (CIs). Pre-specified subgroup analyses were conducted according to individual GKAs (dorzagliatin and all other GKAs), various controls, follow-up duration, mean duration of diabetes, and the location of clinical research.</p><p><strong>Results: </strong>17 RCTs enrolling 4,918 patients (3,196 patients received GKAs and 1,722 patients received placebo or other hypoglycemic drugs) were identified. Among the 17 RCTs, dorzagliatin, AZD1656 and MK-0941 in three trials (1,541 patients), five trials (885 patients), and three trials (798 patients), respectively. GKA treatment was associated with a higher risk of any AEs (OR 1.220, 95% CI 1.072-1.389), mild AEs (OR 1.373, 95% CI 1.085-1.738), hyperlipidemia (OR 1.532, 95% CI 1.071-2.189), and hyperuricemia (OR 2.768, 95% CI 1.562-4.903) compared to patients in the control groups. The higher risks of any AEs were mainly attributed to dorzagliatin and MK-0941 and mild AEs mainly attributed to dorzagliatin. Notably, dorzagliatin had significant effects on the occurrence of hyperlipidemia (OR 1.476, 95% CI 1.025-2.126) and hyperuricemia (OR 2.727, 95% CI 1.523-4.883) in the subgroup analyses. No significant effects were detected from other GKAs when regarding hyperlipidemia and hyperuricemia.</p><p><strong>Conclusion: </strong>The results of our meta-analysis indicated that GKAs were associated with a higher risk of any AEs, mild AEs, hyperlipidemia, and hyperuricemia. Further subgroup analyses revealed that the increased occurrence of hyperlipidemia, and hyperuricemia mainly originated from dorzagliatin treatment.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4539-4552"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Blood Glucose Can Promote Uric Acid Excretion: A Cross-Sectional Study Involving Urinary Glucose and Urinary Uric Acid in China.","authors":"Ya Zhou, Haixiao Wang, Weiyi Gao","doi":"10.2147/DMSO.S472686","DOIUrl":"10.2147/DMSO.S472686","url":null,"abstract":"<p><strong>Purpose: </strong>Uric acid and blood glucose are important indicators of metabolic disorders. Numerous studies have elucidated the association between them, but the focus on their relationship through examination of urinary glucose and uric acid excretion has been limited. In this study, we conducted a comprehensive analysis on these indicators to explain the relationship.</p><p><strong>Patients and methods: </strong>This study involved the recruitment of 2498 patients who underwent fractional excretion of uric acid (FEUA) testing during their hospitalization at the Health Department of Qilu Hospital (Qingdao), Shandong University, between January 2017 and November 2023, with 1416 subjects being included in the final analysis. The included subjects were analyzed based on different genders. One-way analysis of variance, multiple linear regression analysis, and restricted cubic spline were adopted for data analysis.</p><p><strong>Results: </strong>Higher FEUA and lower serum uric acid (SUA) levels were observed in diabetic patients with urinary glucose than in diabetic patients without urinary glucose and the nondiabetic population. FEUA exhibited a proportional increase with elevated blood glucose levels, even including cases that lacked urinary glucose. After adjustment for potential confounding factors, SUA levels did not increase with the increase in fasting blood glucose (FBG) levels, and once FBG levels surpassed a certain threshold leading to glucosuria, FEUA was further elevated, accompanied with a subsequent reduction in SUA levels. There is a stronger linear relationship between SUA or FEUA and FBG levels in women than that in men after adjusting for confounding factors.</p><p><strong>Conclusion: </strong>Hyperglycemia is not considered a risk factor for hyperuricemia. Regardless of the presence of urinary glucose, elevated blood glucose levels can stimulate renal excretion of uric acid. Upon reaching a threshold that induces glucosuria, the SUA levels decrease substantially. Meanwhile, there are some differences in the relationship between SUA or FEUA and FBG among different genders.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4553-4563"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comment on 'Clinical Value of Urinary Wilms' Tumour-1 and Mu-Glutathione S-Transferase Gene Expression in Kidney Injury in Type 2 Diabetes Mellitus: Important Considerations for Clinical Application' [Letter].","authors":"Yong Luo, Zhongying Huang, Jifang Yang","doi":"10.2147/DMSO.S507669","DOIUrl":"https://doi.org/10.2147/DMSO.S507669","url":null,"abstract":"","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4571-4572"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-Existing Ectopic Cortisol-Producing Adenoma and Retroperitoneal Schwannoma, a Rare Case Report.","authors":"Lingfeng Shi, Jiongyu Hu, Xiaoli Xu, Yongquan Wang, Senlin Xu, Lijuan Tu","doi":"10.2147/DMSO.S487334","DOIUrl":"10.2147/DMSO.S487334","url":null,"abstract":"<p><strong>Background: </strong>Ectopic cortisol-producing adrenocortical adenoma (ECPA) is extremely rare, with only a few cases reported. Retroperitoneal schwannoma is also uncommon, accounting for only 0.7-5% of all schwannomas. It is peculiar to have both conditions at the same time, and it is intriguing to explore their possible connection. Herein, we present a case of both ECPA and retroperitoneal schwannoma and provide our conjectures regarding their co-occurrence.</p><p><strong>Case presentation: </strong>A 38-year-old female presented with a two-year history of facial and lower limb edema, as well as chest tightness and palpitations for the past four months. Physical examination revealed hypertension, a high body mass index (BMI), moon face, thick neck and back fat, abdominal obesity, and purple striae on the abdomen. Laboratory tests indicated an persistent increased cortisol level and suppression of adrenocorticotropic hormone (ACTH). Adrenal-enhanced computed tomography (CT) scan showed that both adrenal glands appeared normal without evident adenomas or hyperplasia. However, the scan revealed two lesions located in the right renal hilum and retroperitoneal area positioned anteriorly to the lower margin of the lumbar 2 pyramid. Further imaging using ⁶⁸Ga-DOTATATE PET/CT revealed concentrated radiotracer uptake in the tumor at the right renal hilum, indicating it may be responsible for the patient's Cushing's symptoms. After laparoscopic resection of these masses, clinical symptoms improved significantly. Postoperative pathology confirmed the right renal hilum one lesion as an ECPA while identifying another lesion as a schwannoma.</p><p><strong>Conclusion: </strong>Our literature reported a case with the diagnosis of both ECPA in the right renal hilum and retroperitoneal schwannoma. ⁶⁸Ga-DOTATATE PET/CT imaging can provide functional and locational information on tumors, enabling a comprehensive examination of the entire body to identify lesions that require appropriate treatment.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4565-4570"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acupuncture and Drug Combination Therapy for Abnormal Glucose Metabolism: Exploring Synergistic Enhancement and Reduced Toxicity Mechanisms.","authors":"Xinyi Tian, Wenjun Wang, Lu Zhang, Liuqing Wang, Kaiqi Zhang, Xiaolei Ge, Zhengrong Luo, Yaqian Zhao, Xu Zhai, Chunjing Li","doi":"10.2147/DMSO.S492626","DOIUrl":"https://doi.org/10.2147/DMSO.S492626","url":null,"abstract":"<p><p>This review examines the impact of combining acupuncture with drug therapy on abnormal glucose metabolism and investigates their underlying mechanisms. Conditions like diabetes pose significant health risks due to irregular glucose metabolism. Traditional drug treatments often encounter challenges related to side effects and drug resistance. Acupuncture, as a non-pharmacological intervention, is thought to enhance glucose metabolism and mitigate medication side effects. We selected the relevant studies of acupuncture or electroacupuncture combined with drugs in the treatment of abnormal glucose metabolism in the past five years, and the results indicate that the combination of acupuncture or electroacupuncture and drug therapy markedly enhances glucose metabolism and mitigates medication-related side effects such as gastrointestinal discomfort and hypoglycemia. Overall, this review underscores the synergistic benefits of acupuncture and drug therapy in improving treatment efficacy and reducing adverse effects, offering promising new approaches for managing abnormal glucose metabolism. Our review provides evidence for the potential benefits of combining acupuncture with drug therapy for abnormal glucose metabolism, which could lead to improved treatment outcomes and reduced side effects for patients with type 2 diabetes mellitus.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4525-4537"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Techniques for Implementing Continuous Glucose Monitoring in Primary Care: Key CGM Updates and Highlights from the EASD2024 Conference [Podcast].","authors":"Jennifer Green","doi":"10.2147/DMSO.S503949","DOIUrl":"10.2147/DMSO.S503949","url":null,"abstract":"<p><p>This article discusses innovations, advancements, and discoveries in continuous glucose monitoring (CGM) that were presented at the European Association for the Study of Diabetes 2024 Conference in Madrid, Spain, held in September 2024. Specifically, the author will discuss data from studies that discuss the impact of CGM on hemoglobin A1C in people with type 2 diabetes; the impact of CGM use in hospitalization settings for people with diabetes; the effectiveness of CGM in those who have undergone cardiac surgery; the efficacy of real-time CGM in adults hospitalized with diabetic ketoacidosis; time in rage in older individuals; and new devices for glucose sensing.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4463-4468"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142778946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a) is Associated with Sarcopenia in Patients with Type 2 Diabetes: A cross-Sectional Study.","authors":"Wen Wei, Fenyan Lv, Shuling Liu, Hui Cao, Ruiyu Lin, Hangju Chen, Mei Tu, Baozhen Cao","doi":"10.2147/DMSO.S489605","DOIUrl":"https://doi.org/10.2147/DMSO.S489605","url":null,"abstract":"<p><strong>Background: </strong>The association between lipoprotein(a) (Lp(a)) and sarcopenia in T2DM patients of general age is unclear, and whether this association differs by sex remains uncertain. We intend to analyze the association between Lp(a) and sarcopenia in patients with type 2 diabetes mellitus (T2DM) and whether this association differs by sex.</p><p><strong>Methods: </strong>T2DM patients between December 2021 and December 2022 were consecutively enrolled. Sarcopenia was defined according to the criteria of Consensus of the Asian Working Group for Sarcopenia (AWGS) 2019.A multivariable logistic regression model was used to calculate the odds ratio of Lp(a)≥30 mg/dL for sarcopenia in total T2DM patients and in all sexes. Restricted cubic splines were also used to evaluate the association between Lp(a) and sarcopenia.</p><p><strong>Results: </strong>Among the 426 patients, the mean age was 58.6 years and 56.3% were males. The prevalence of sarcopenia was 31.7% in total patients, 34.2% in male and 28.5% in female. The percentages of Lp(a)≥30 mg/dL were 19.0% in total patients. Compared with patients in Lp(a)<30 mg/dL group, those in Lp(a)≥30 mg/dL group showed an increased risk of sarcopenia (adjusted odds ratio [aOR]: 2.19, 95% CI: 1.09 to 4.39, p = 0.027). Results from restricted cubic splines were robust. When analyzing each sex, there was also a significant association between Lp(a)≥30 mg/dL and sarcopenia (male: aOR: 2.59, 95% CI: 1.09 to 6.21, p = 0.032; female: aOR: 2.45, 95% CI: 1.06 to 6.03, p = 0.039).</p><p><strong>Conclusion: </strong>In T2DM patients, elevated Lp(a) was associated with an increased risk of sarcopenia and such an association did not differ by sex. Screening for sarcopenia should be emphasized in T2DM patients with Lp(a)≥30 mg/dL, both men and women.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4511-4524"},"PeriodicalIF":2.8,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Analysis of Hypoglycemic Fear and Psychological Well-Being and Family Support Function in Older Adults Diabetic Patients.","authors":"Xia Ren, Zhaoxia Tian, Hongmei Li","doi":"10.2147/DMSO.S486509","DOIUrl":"10.2147/DMSO.S486509","url":null,"abstract":"<p><strong>Background: </strong>Aging diabetic patients have an increased incidence of hypoglycemia due to long disease history, multiple medications, and other factors. The higher the frequency of hypoglycemia, the greater the fear of it, and the heavier the psychological burden. This fear can have a significant negative impact on the patient's personal psychological distress related to the disease, self-care, and the quality of life of other family members. Therefore, analyzing the factors contributing to the fear of hypoglycemia is crucial for finding effective ways to overcome them.</p><p><strong>Objective: </strong>To analyze the correlation between hypoglycemic fear (FOH), psychological well-being, and family support function in older adults patients with diabetes mellitus (DM).</p><p><strong>Methods: </strong>Seventy-eight older adults patients with DM were recruited from the community for the study. The Chinese version of the hypoglycemia fear survey scale (CHFSII-WS), WHO-5 happiness index scale and family support function scale were used to analyze the influencing factors of FOH in older adults DM patients to clarify the correlation between FOH, psychological well-being, and family support function.</p><p><strong>Results: </strong>Low academic qualification, long course of disease, the frequency of hypoglycemia episodes > 2 in the last one year were the risk factor for FOH in older adults DM patients, and hypoglycemia prevention education, psychological well-being and family support function were protective factors. Family support function had a mediating effect.</p><p><strong>Conclusion: </strong>Older adults patients with DM have higher levels of FOH, which has many influencing factors, and family support function has an obvious mediating effect between FOH and psychological well-being. High-intensity FOH can be improved by actively developing hypoglycemia prevention education for patients and caregivers and improving family support function and psychological well-being.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4501-4509"},"PeriodicalIF":2.8,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Physical Activity, VO_2max, and Visfatin on Relationship Between BMI and Chronic Inflammation.","authors":"Liqiang Su, Shouzhi Wu, Jinmei Fu, Shunli Sun","doi":"10.2147/DMSO.S473266","DOIUrl":"https://doi.org/10.2147/DMSO.S473266","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to explore the relationship between BMI and chronic inflammation and to investigate the interaction and mediation of physical activity (PA), cardiopulmonary function, and visfatin.</p><p><strong>Methods: </strong>A total of 119 participants were included in the study, 60 in the obesity group, 30 in the normal weight group, and 29 in the overweight group. PA, VO_2max, visfatin, high-sensitivity C-reactive protein (hs-CRP), and four blood lipid indices (TC, TG, HDLC, LDLC) were analyzed. Regression analysis was used to understand the effect of BMI on chronic inflammation. Covariate analysis was conducted to screen effective covariates affecting BMI to predict chronic inflammation and test the interaction and intermediary role of effective covariates.</p><p><strong>Results: </strong>The increase in BMI could aggravate chronic inflammation. PA, VO_2max, and visfatin had interactive effects on BMI affecting chronic inflammation, and visfatin played an intermediary role in BMI affecting chronic inflammation. The effect value of BMI on chronic inflammation in terms of low PA was 3.5 times higher than that of high PA, that of low VO_2max was 2.8 times higher than that of high VO_2max, and that of high visfatin was 3.65 times higher than that of low visfatin. Approximately 19.35% of the effect was mediated by visfatin.</p><p><strong>Conclusion: </strong>An increase in BMI can aggravate chronic inflammation. Increases in PA and VO_2max can alleviate chronic inflammation, and visfatin plays a positive mediating role.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4489-4500"},"PeriodicalIF":2.8,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Metabolic and Obesity Phenotypes and Diabetes Risk in Children and Adolescents.","authors":"Huiling Hao, Yanhua Su, Mei Feng","doi":"10.2147/DMSO.S484639","DOIUrl":"https://doi.org/10.2147/DMSO.S484639","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes is a significant public health concern worldwide, having increased rapidly in recent decades among younger generations. The correlation between metabolic/obesity phenotypes and the development of pre-diabetes in children and adolescents remains unclear.</p><p><strong>Methods: </strong>This study aimed to explore this association within a cohort of 1,524 subjects aged 7 to 18 years. Subjects were categorized into four groups based on their metabolic and obesity status: Metabolically Unhealthy with Normal Body Weight (MUNW), Metabolically Healthy Overweight/Obesity (MHO), Metabolic Healthy with Normal Body Weight (MHNW), and Metabolically Unhealthy Overweight/Obesity (MUO). Physical parameters such as body mass, as well as biochemical markers including blood pressure, fasting glucose, triglycerides, and high-density lipoprotein cholesterol, were measured.</p><p><strong>Results: </strong>A total of 61.9% of children were within the normal range for both body weight and metabolism (MHNW), while 24.4% were classified as MUNW, 5.7% as MHO, and 8% as MUO. The risks of diabetes in the MUNW and MUO groups were 8.89 and 9.18 times higher than in the MHNW group for boys, and 8.15 and 11.24 times higher for girls (P<0.05).</p><p><strong>Conclusion: </strong>These findings suggest that abnormal metabolism, irrespective of body weight, significantly increases the risk of diabetes, while obesity alone does not predict pre-diabetes unless accompanied by metabolic dysregulation. Metabolic markers may serve as more sensitive indicators for assessing diabetes risk in this population.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4479-4487"},"PeriodicalIF":2.8,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}